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I have a 75-year-old male patient with a history of hypertension and mild renal impairment awaiting EVAR for
treatment of a 6 cm infrarenal AAA. However, his CT angiogram shows that he has severe bilateral renal artery
stenoses. Is there any evidence that I should angioplasty or stent these prior to the EVAR?Objectives: To identify evidence to guide the vascular surgeon as to the relevance of renal artery stenting in a
patient with symptomatic renal artery stenosis undergoing elective endovascular aortic aneurysm repair (EVAR).
Methods: A comprehensive literature search of MEDLINE was performed without time limits. The following terms
were used in the ﬁrst instance: renal artery stenting and renal artery stenosis, and any other analogous terms
identiﬁed during the search. Selection criteria were set to randomised control trials.
Results: Despite several large, randomised controlled trials investigating renal artery stenting against medical
treatment alone in symptomatic renal artery stenosis, there has been no signiﬁcant beneﬁt identiﬁed in terms of
improvement in renal function, control of blood pressure, or need for dialysis. The stented populations were also
more likely to suffer from complications caused by the procedure such as bleeding, cholesterol embolisation and
ﬂash pulmonary oedema.
Conclusion: There is no evidence for the use of renal artery stenting over optimal medical management in the
treatment of patients with symptomatic atherosclerotic renal artery stenosis, irrelevant of the degree of stenosis.
In the setting of EVAR, prevention of deterioration of renal function should be with involvement of the renal
physicians, adequate hydration, and use of minimal contrast agent. Repair should be undertaken in centres with
access to 24-hour haemoﬁltration services.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Patients with abdominal aortic aneurysms (AAAs) and
occlusive arterial disease often have concomitant athero-
sclerotic renal artery stenosis (RAS; Fig. 1).1 RAS can be
associated with hypertension, progressive ischaemic ne-
phropathy, renal failure, and eventually lead to renal
replacement therapy.2 Following endovascular AAA repair
(EVAR), a 10% decrease in creatinine clearance in the ﬁrst
year has been observed, independent of the type of graft or
the use of suprarenal ﬁxation.3 There are likely to be several
factors inﬂuencing this decline, including progressive
atherosclerotic disease, pre-existing impairment and the
effects of contrast induced nephropathy (CIN).4responding author. St George’s Vascular Institute, St George’s
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//dx.doi.org/10.1016/j.ejvs.2015.01.019Baseline renal dysfunction prior to EVAR is associated
with peri-operative mortality rates as high as 27%.4
Consequently, for a patient with bilateral atherosclerotic
RAS, hypertension, and mild renal impairment, preventa-
tive measures should be considered to prevent worsening
dysfunction and therefore improve peri-operative
outcome.
Single case reports have demonstrated the usefulness of
successful renal artery stenting in speciﬁc scenarios. One such
report described a patient awaiting repair of a thoraco
abdominal aneurysm with uncontrolled hypertension, wors-
ening heart failure, and progressive renal insufﬁciency (serum
creatinine: 3.8 mg/dL), caused by a high-degree (80%)
atherosclerotic RAS in a solitary functioning kidney.Treatment
led to normalisation of serum creatinine and blood pressure
prior to successful surgical treatment of the aneurysm.5
EVIDENCE FOR RENAL ARTERY STENTING IN RAS
For patients without such clear manifestations of RAS, there
is little evidence that treatment with renal artery stenting
Figure 1. Case study: CT angiogram of a 72-year-old woman pre-
senting with 5.6 cm infra-renal AAA and a background of chronic
renal disease (eGFR 27). Imaging demonstrated a right renal artery
occlusion, and left RAS. Management included pre-operative
optimisation, sodium chloride intravenous hydration 24 hours
pre-EVAR, and post-operative monitoring in a level-2 setting. Post-
operatively, eGFR improved to 33. The patient was discharged
without any complications.
Table 1. Approach to Medical optimization of the patient with
atherosclerotic RAS and impaired renal function.10
1. Management of hypertension:
 Target blood pressure <140/90 mmHg
2. 10 mg of atorvastatin, titrated to 20 mg as
tolerated (irrelevant of lipid levels)
3. Aspirin 75e100 mg o.d.
4. Smoking cessation counselling
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Meta-analysis of three small randomised controlled trials of
renal artery stenting compared with medical therapy alone
failed to demonstrate signiﬁcant improvements in serum
creatinine or blood pressure in a combined total of 210
patients followed up to 6 months.6e9 Since then, several
larger multicentre randomised trials have looked into the
effects of stenting in this group of patients.
The STAR trial recruited 140 patients with a creatinine
clearance of less than 80 mL/min/1.73 m2 and stenosis of
50% or greater, and randomised them to renal artery
stenting plus medical therapy versus medical therapy alone
(Table 1).10 The primary endpoint was a >20% decrease in
creatinine clearance in the absence of arterial restenosis.
There was no signiﬁcant difference between the two
groups: 16% of patients (10/64) in the stent placement
group reached primary endpoint compared with 22% (16/
76) in the medication group. Stenting was associated with
several complications, including three deaths (two following
renal artery perforation, one septic haematoma). Morbidity
was caused by false aneurysms of the femoral artery (two),
and deteriorating renal function and dialysis following
cholesterol embolisation. In conclusion, stenting did not
demonstrate beneﬁt in impaired renal function compared
with medical therapy alone and led to a number of signif-
icant procedure-related complications. Of 140 patients, 33%
had only mild (50e70%) atherosclerotic RAS on invasive
imaging. Furthermore, 12/64 patients in the stenting arm
with stenosis <50% did not receive a stent but were still
analysed in the intention-to-treat analysis. Six patients also
did not receive a stent (one angioplasty only, one mortality
pre-placement, two declined, two technical failures) despite
inclusion in analysis for the intention-to-treat cohort.
The larger and more robust Angioplasty and STenting for
Renal Artery Lesions (ASTRAL) trial was a multicentre
randomised unblinded clinical trial, recruiting 806 patients
with atherosclerotic renovascular disease.11 Patients were
randomised to undergo angioplasty and stenting plusmedical therapy or medical therapy alone (as per the local
centre protocols e management of hypertension, statin,
and anti-platelet). Primary outcome was creatinine clear-
ance out to 5 years. Secondary outcomes included blood
pressure, time to ﬁrst renal or major cardiovascular event,
and mortality. As with studies before it, there were no
signiﬁcant differences in primary outcome between any
cohort (p ¼ .06), although there appeared to be a trend
towards favourable results in the stenting group. This lack of
beneﬁt persisted even after subgroup analysis for varying
degrees of renal artery stenosis (p ¼ .23). Over the course
of the study, 31 serious complications of revascularisation
occurred in 23 (9%) patients (Table 2). There was no
apparent overall clinical beneﬁt from revascularisation
compared with medical therapy alone in those with any
degree of atherosclerotic renovascular disease. Of note,
patients were only enrolled if their referring physician felt
there was equipoise between stenting and medical treat-
ment. In addition, individuals requiring revascularisation
within 6 months were excluded. Only 83% of the patients
randomised to stenting underwent the procedure. This may
be because one-quarter of the patients had normal renal
function at baseline, and 41% had less than 70% athero-
sclerotic renal artery stenosis on invasive imaging.
The most recent, multicentre open-label randomised
controlled trial was the Cardiovascular Outcomes in Renal
Atherosclerotic Lesions (CORAL) study. It also compared
medical therapy alone versus medical therapy plus stenting
in 947 patients with RAS and chronic kidney disease, hy-
pertension, or both.12 Patients were categorised by degree
of arterial stenosis (60e80%, 80e99%). Hypertension was
classed as a systolic pressure of >155 mmHg despite two
anti-hypertensive agents, and chronic kidney disease an
eGFR <60 mL/min/1.73 m2. The protocol for medical
therapy required use of the angiotensin II type-1 receptor
blocker candesartan (with or without hydrochlorothiazide)
and the combination agent amlodipineeatorvastatin. The
dose was adjusted to achieve targets of <140/90 mmHg in
patients without comorbidities, and less than 130/80 mm
Hg in patients with diabetes or chronic kidney disease.
Endpoints were progressive renal insufﬁciency and need
for renal replacement therapy out to 2 years. They found no
signiﬁcant difference between the two groups in terms of
decline in renal function (stenting: 68/459 [14.8%], medical
therapy alone: 77/472 patients [16.3%], p ¼ .58), or
decrease in systolic blood pressure (p ¼ .03). The CORAL
investigators concluded that renal artery stenting did not
Table 2. Complications following renal artery stenting in ASTRAL trial.11
Peri-procedural complications (within 24 hours) Revascularisation (N ¼ 335) Medical therapy (N ¼ 24)
Renal or stent embolisation 5 (1.5%) 0 (e)
Renal arterial thrombosis or occlusion 4 (1%) 0 (e)
Renal arterial perforation or dissection 3 (1%) 1 (4%)
Non-renal embolisation leading to peripheral
gangrene and amputation of toes or limbs
3 (1%) 0 (e)
Stent misplacement requiring additional stent 10 (3%) 0 (e)
Distal stent retrieval or deployment 1 (0.3%) 0 (e)
Balloon rupture 1 (0.3%) 0 (e)
Need for surgical rescue 0 (e) 0 (e)
Access vessel damage 7 (2%) 0 (e)
Pulmonary oedema 1 (0.3%) 0 (e)
Femoral artery aneurysm at puncture site 1 (0.3%) 0 (e)
Myocardial infarction 1 (0.3%) 0 (e)
Number of events/number of patients 37/30 1/1
Post-operative complications (between 24 hours
and 1 month post procedure)
(N ¼ 280)
Groin haemorrhage/haematoma 32 (11%)
Deterioration in renal function 30 (11%)
Pseudoaneurysm 3 (1%)
Renal artery occlusion 1 (0.4%)
Local infection at puncture site 1 (0.4%)
Death within 30 days 2 (0.7%)
Number of events/number of patients 69/55
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hensive medical treatment, over that seen with medical
treatment alone.12MEDICAL MANAGEMENT AND PERI-OPERATIVE RENAL
PROTECTION
Best medical therapy should include optimal glycaemic
control, aspirin, and statin therapy, smoking cessation
advice, and blood pressure control using an appropriate
agent.12 Studies suggest that target systolic pressure should
be 140/90 or less, especially where there is co-existing
comorbidity.13
EVAR can lead to renal injury even in those with normal
function pre-operatively, evidenced by rises in several bio-
markers of renal damage such as serum creatinine, urinary
retinol-binding protein, and albumin/creatinine ratio.14 CIN
(deﬁned as 25% increase in estimated glomerular ﬁltra-
tion rate at 48 hours) affects up to 20e30% of patients with
pre-existing renal impairment, and is associated with
increasing length of stay and higher mortality at 1 year.15
Recommendations for preventative strategies from the
European Society of Vascular Surgery include adequate pre-
and post-procedural ﬂuid administration, involvement of a
renal physician for guidance on optimisation of medications
and restricting repair to those centres with 24-hour access
to haemoﬁltration.16
The usefulness of anti-oxidant compounds such as N-
acetylcysteine (NAC), sodium bicarbonate, and ascorbic acid
is debatable.These compounds act by scavenging a variety of
oxygen free radicals, protecting renal tissue and DNA from
direct damage. Their effects on CIN must be extrapolated
from work performed in the setting of coronary and pe-
ripheral angiography, which as a rule use less contrastmaterial than EVAR. A detailed meta-analysis of trials looking
at sodium bicarbonate versus normal saline for prevention of
CIN in those undergoing cardiac or peripheral angiography
found an apparent beneﬁt for bicarbonate administration
(odds ratio 0.41 in patients with pre-existing renal failure) in
a combined cohort of 1539 patients across seven trials.17 This
did not extend to any differences in mortality rates, heart
failure, or development of end stage renal failure between
groups, irrelevant of pre-existing renal function. A rando-
mised trial investigating various hydration strategies to
attenuate CIN in 326 patients receiving intravenous contrast
found the combination of intravenous sodium bicarbonate
and NAC most effective.18 There is little evidence for anti-
oxidant strategies in patients undergoing EVAR. In a small
randomised study of 20 men undergoing EVAR, NAC
administration had no attenuating effect on degree of acute
renal injury in the peri-operative period.14 It is clinically
relevant to note that serum creatinine, and therefore esti-
mated glomerular ﬁltration rate are relatively slow markers
of renal injury. Future research lies in identiﬁcation of novel
biomarkers to allow earlier identiﬁcation of CIN.19CONCLUSION
Current evidence does not support renal artery angioplasty/
stenting over medical treatment alone for the management
of either symptomatic or asymptomatic atherosclerotic RAS,
regardless of the degree of stenosis. No randomised
controlled or observational studies have so far evaluated
whether or not revascularisation of a symptomatic RAS
protects from the adverse effects that EVAR might inﬂict on
kidney function. Pre-operative review by a renal physician,
early admission for intravenous hydration pre-EVAR, and
minimising contrast use during the procedure are likely to
Table 3. Guidelines for renal investigation and optimisation in
patients undergoing EVAR.16
1. Pre-operative serum creatinine and estimated
glomerular ﬁltration rate in all patients
2. Review by renal physician pre-operatively for
all patients with pre-existing renal failure
3. Optimisation of medications
4. Adequate pre-operative hydration
5. AAA repair to be undertaken in hospitals with
access to 24 hour on-site haemoﬁltration
6. Techniques to minimise contrast use/use of
alternative contrast medium, e.g. CO2
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some evidence recommending use of anti-oxidant agents
for pre-operative hydration over normal saline alone. Close
monitoring of markers of acute kidney injury in the post-
operative period should continue for at least 48 hours to
allow for any potential rise in serum creatinine to be
observed and acted upon.
There is no evidence supporting the use of angioplasty or
stenting of the bilateral RAS of the male patient described
in this clinical vignette prior to EVAR. Conservative man-
agement and pre-operative optimisation of renal function
together with close post-operative monitoring of renal
function are adequate measures for the management of the
bilateral RAS in this patient with symptomatic RAS and
concomitant AAA.
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